'Deadly Risk' of Fat-Loss Drugs
Newsweek Europe|March 22, 2024
Diabetes treatment Ozempic has become popular among dieters due to its weightloss side effect, but a study warns of a link between the drug and suicidal thoughts
PANDORA DEWAN
'Deadly Risk' of Fat-Loss Drugs

"MIRACLE" FAT-MELTING DRUG OZEMPIC HAS been linked in a study to a series of rare but potentially fatal psychiatric episodes, scientists have warned.

The injectable prescription drug was developed to manage blood sugar levels in patients with Type 2 diabetes, but it has gained popularity and gone viral on social media due to one sought-after side effect: weight loss.

Ozempic is based on a naturally occurring human hormone called glucagon-like peptide 1, which plays an important role in regulating appetite and blood sugar levels. Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its receptors.

In doing so, semaglutide induces feelings of fullness while delaying the emptying of our stomach, making us less hungry and therefore less likely to overeat.

Semaglutide is also used in Ozempic's sister drug, Wegovy, which has been approved by the FDA for chronic weight management. Between the start of 2020 and the end of 2022, prescriptions of GLP-1 mimic medications like semaglutide increased by 300 percent across the U.S., according to health care analytics firm Trilliant Health.

The drug has since been endorsed by celebrities and influencers, with #ozempic reaching over 1.4 billion views on TikTok. However, when used as a weight-loss drug, semaglutide has been shown to have some uncomfortable side effects.

Most studies into these have focused on gut problems, but a new study, published in the International Journal of Clinical Pharmacy, has highlighted a concerning association between semaglutide and adverse psychiatric events, including depression, anxiety and suicidal thoughts. Pharmaceutical manufacturer Novo Nordisk, which produces Ozempic and Wegovy, cited the FDA saying that no evidence was found regarding suicidal thoughts or actions caused by these medicines.

この記事は Newsweek Europe の March 22, 2024 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

この記事は Newsweek Europe の March 22, 2024 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

NEWSWEEK EUROPEのその他の記事すべて表示
The Fight To Ban Child Marriage
Newsweek Europe

The Fight To Ban Child Marriage

Under-18s can legally wed in most U.S. states but young spouses are often left physically, emotionally and economically vulnerable, campaigners say

time-read
10 分  |
June 21 - 28, 2024 (Double Issue)
Major League Error
Newsweek Europe

Major League Error

Why baseball fans have long thought Ty Cobb to be a racist when he wasn't

time-read
5 分  |
June 21 - 28, 2024 (Double Issue)
The TikTok Election
Newsweek Europe

The TikTok Election

With both Donald Trump and Joe Biden now on the app, could it help determine the next U.S. president in November?

time-read
4 分  |
June 21 - 28, 2024 (Double Issue)
Failure to Deliver
Newsweek Europe

Failure to Deliver

Multinational companies embraced Chinese factories to lower costs. Their excessive reliance ended up being a central cause of the COVID supply chain meltdown

time-read
5 分  |
June 21 - 28, 2024 (Double Issue)
BEST SPECIALISTS & SURGEONS
Newsweek Europe

BEST SPECIALISTS & SURGEONS

FINDING THE BEST MEDICAL SPECIALIST IS A DAUNTING TASK for anyone requiring specific treatment.

time-read
3 分  |
June 21 - 28, 2024 (Double Issue)
SURGEONS MAGIC TOUCH
Newsweek Europe

SURGEONS MAGIC TOUCH

Americans turn down syringes but go UNDER SCALPELS. What do these doctors know that the rest of medicine doesn't?

time-read
10 分  |
June 21 - 28, 2024 (Double Issue)
ARABIAIAN MIGHT
Newsweek Europe

ARABIAIAN MIGHT

SAUDI ARABIA'S INCREASING STRENGTH MEANS IT NOW HAS MUCH MORE CLOUT WITH ITS PARTNERS, INCLUDING THE U.S.

time-read
10+ 分  |
June 14, 2024
Bringing Trump's Trial to Life
Newsweek Europe

Bringing Trump's Trial to Life

Sketch artist Isabelle Brourman tells Newsweek what it was like covering the former president’s court case

time-read
4 分  |
June 14, 2024
Iran Examines the Nuclear Option
Newsweek Europe

Iran Examines the Nuclear Option

Tehran’s rhetoric could spark an arms race in the Middle East like never before

time-read
10+ 分  |
June 14, 2024
Climate Conviction at What Price?
Newsweek Europe

Climate Conviction at What Price?

Fifty years ago experts doubted Americans would pay to save the environment. Only some of their fears are still true

time-read
8 分  |
June 14, 2024